immateri focu upcom filgotinib uc
phase ra approv
financi larg immateri share lower revenu opex
vs con broadli similar underli loss burn outlook trim
trial delay vs jefe optimist upcom
filgotinib phase select data ulcer coliti posit
arthriti approv initi toledo deprioritis select
phase iia start first efficaci
optimist upcom select data phase select data evalu
inhibitor filgotinib ulcer coliti uc on-track
previous outlin placebo-adjust remiss
induct would competit notabl recent kol
call expert enthusiast jak inhibitor oral option inflammatori
bowel diseas particularli crohn felt would perhap challeng
filgotinib differenti safeti vs xeljanz
forecast ww peak sale filgotinib ra crohn
diseas uc cumul contribut indic
combin worth npv probabl
ra approv still expect uncertain delay on-going filgotinib trial
glpg partner gilead still anticip fda eu japanes approv
rheumatoid arthriti ra gilead filgotinib manufactur site
good stand fda gmp certifi inspect lead
delay light pandem recruit filgotinib trial
paus like lead delay phase crohn diseas data
phase psoriat arthriti data among other
phase ankylos spondyl trial expect initi
fund rapidli advanc pipelin ziritaxestat phase
isabela trial lung fibrosi ipf target patient enrol
recruit slow due interim analysi anticip
final data phase ii system sclerosi due readout
ziritaxestat contribut npv base probabl ww
peak sale ipf expect signific proport gilead
use acceler glpg secret toledo programm order maximis
first-mov advantag undisclos mechan action develop
second-gen compound prioritis given superior
profil due start extens phase iia proof-of-concept programm across
multipl inflammatori indic data assum
peak sale broad programm probabl npv
phase iia pinta data also ipf expect data
phase iib rocella trial osteoarthr expect
trigger opt-in period gilead us right forecast ww peak
sale npv probabl servier ex-u right
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
galapago belgian biotech compani focus drug discoveri use cell taken patient diseas interest
typic musculoskelet inflammatori disord plu orphan indic compani advanc product
filgotinib inhibitor complet phase rheumatoid arthriti also develop crohn diseas
ulcer coliti partner gilead compani broad collabor gilead also activ collabor
servier morphosi
price base sum-of-the-part valuat largley compris probability-adjust npv filgotinib
ipf osteoarthr toledo autoimmun disord plu net risk includ regulatori setback
filgotinib upcom late-stag pipelin catalyst high risk clinic trial failur
pt base view remain cheap low-expect stori get better achiev even
earn line pharma peer risk competit pipelin disappoint worse-than-
peter welford cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
philippa gardner eng certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli
indirectli relat specif recommend view express research report
luci codrington certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
colin white phd certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
registr non-u analyst peter welford cfa employ jefferi intern limit non-u affili jefferi
llc registered/qualifi research analyst finra analyst may associ person jefferi
llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
registr non-u analyst philippa gardner eng employ jefferi intern limit non-u affili
jefferi llc registered/qualifi research analyst finra analyst may associ person
jefferi llc finra member firm therefor may subject finra rule restrict commun
subject compani public appear trade secur held research analyst
registr non-u analyst luci codrington employ jefferi intern limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
registr non-u analyst colin white phd employ jefferi intern limit non-u affili jefferi llc
registered/qualifi research analyst finra analyst may associ person jefferi llc
finra member firm therefor may subject finra rule restrict commun subject
compani public appear trade secur held research analyst
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom
seek updat research appropri variou regul may prevent us asid certain industri
pleas see import disclosur inform page report
report publish period basi larg major report publish irregular interv appropri analyst
articl articl
jefferi llc act financi advisor kite pharma kite sale compani
jefferi group llc make market secur adr galapago
jefferi group llc make market secur adr inc
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold
rate secur averag secur price consist expect total return price appreci plu yield
plu minu within period under-perform rate secur averag secur price consist
expect total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi
project opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf
averag group price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month
period stock select base fundament analysi may take account factor analyst convict
differenti analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi
franchis pick includ buy rate stock number vari depend analyst recommend inclus
stock ad new opportun aris remov reason inclus chang stock met desir
return longer rate buy and/or trigger stop loss stock day volatil bottom quartil
stock continu stop loss remaind stop franchis pick intend repres
recommend portfolio stock sector base may note believ pick fall within invest
style growth valu
risk may imped achiev price target
pleas see import disclosur inform page report
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken
indic guarante futur result price valu incom financi instrument mention
report rise well fall may affect chang econom financi polit factor financi instrument
denomin currenc investor home currenc chang exchang rate may advers affect price
valu incom deriv financi instrument describ report addit investor secur adr
whose valu affect currenc underli secur effect assum currenc risk
compani mention report
rate price target histori galapago glpg na
rate price target histori galapago glpg
rate price target histori inc
jefferi llc act financi advisor kite pharma kite sale compani
pleas see import disclosur inform page report
